Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chronic amphetamine treatment decreases cocaine consumption in preclinical and human laboratory studies and in clinical trials. Lisdexamfetamine is an amphetamine prodrug in which L-lysine is conjugated to the terminal nitrogen of d-amphetamine. Prodrugs may be advantageous relative to their active metabolites due to slower onsets and longer durations of action; however, lisdexamfetamine treatment's efficacy in decreasing cocaine consumption is unknown. METHODS: This study compared lisdexamfetamine and d-amphetamine effects in rhesus monkeys using two behavioral procedures: (1) a cocaine discrimination procedure (training dose = 0.32mg/kg cocaine, i.m.); and (2) a cocaine-versus-food choice self-administration procedure. RESULTS: In the cocaine-discrimination procedure, lisdexamfetamine (0.32-3.2mg/kg, i.m.) substituted for cocaine with lower potency, slower onset, and longer duration of action than d-amphetamine (0.032-0.32mg/kg, i.m.). Consistent with the function of lisdexamfetamine as an inactive prodrug for amphetamine, the time course of lisdexamfetamine effects was related to d-amphetamine plasma levels by a counter-clockwise hysteresis loop. In the choice procedure, cocaine (0-0.1mg/kg/injection, i.v.) and food (1g banana-flavored pellets) were concurrently available, and cocaine maintained a dose-dependent increase in cocaine choice under baseline conditions. Treatment for 7 consecutive days with lisdexamfetamine (0.32-3.2mg/kg/day, i.m.) or d-amphetamine (0.032-0.1mg/kg/h, i.v.) produced similar dose-dependent rightward shifts in cocaine dose-effect curves and decreases in preference for 0.032mg/kg/injection cocaine. CONCLUSIONS: Lisdexamfetamine has a slower onset and longer duration of action than amphetamine but retains amphetamine's efficacy to reduce the choice of cocaine in rhesus monkeys. These results support further consideration of lisdexamfetamine as an agonist-based medication candidate for cocaine addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.019 · Cited by 616
DOLE, V. P. (1966) · Archives of Internal Medicine · doi:10.1001/archinte.1966.00290160004002 · Cited by 290
Controversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270 · cited 2×
“The use of preclinical choice procedures may facilitate the translation of results to human laboratory studies that also rely almost exclusively on choice procedures (Comer et al., 2008; Haney and Spealman, 2008).”
MethodDextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243 · cited 2×
“…choice by chronic d-amphetamine treatment in monkeys are consistent with clinical effectiveness of amphetamine maintenance to reduce cocaine use (Grabowski et al., 2001; Mariani et al., 2012), these results suggest that lisdexamfetamine may also be clinically effective to reduce cocaine use.”
BackgroundGrabowski, J., Rhoades, H., Stotts, A., Cowan, K., Kopecky, C., Dougherty, A., Moeller, F. G., Hassan, S., & Schmitz, J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300392 · Cited by 185 · cited 2×
“In the development of an agonist-based pharmacotherapy for cocaine addiction, there are at least three desirable attributes the compound should possess (Grabowski et al., 2004b; Rothman et al., 2005).”
BackgroundAbsorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · cited 3×
“…after intramuscular administration consistent with previous pharmacokinetic results reported after i.v. (Jasinski and Krishnan, 2009a) and oral (Jasinski and Krishnan, 2009b; Ermer et al., 2010) administration in humans and intraperitoneal administration in rats (Rowley et al., 2012).”
BackgroundResultInfluentialEffects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124 · cited 1×
“…have demonstrated efficacy to reduce cocaine-taking behaviors across a broad range of experimental endpoints in humans (Grabowski et al., 2001; Mooney et al., 2009; Greenwald et al., 2010; Rush et al., 2010), nonhuman primates (Negus, 2003; Czoty et al., 2011), and rodents (Chiodo et al.,…”
BackgroundJasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093841 · Cited by 100
Mariani, J. J., Pavlicova, M., Bisaga, A., Nunes, E. V., Brooks, D. J., & Levin, F. R. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.032 · Cited by 85
Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009357346 · Cited by 72
Rowley, H. L., Kulkarni, R., Gosden, J., Brammer, R., Hackett, D., & Heal, D. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.008 · Cited by 64 · cited 4×
“…after intramuscular administration consistent with previous pharmacokinetic results reported after i.v. (Jasinski and Krishnan, 2009a) and oral (Jasinski and Krishnan, 2009b; Ermer et al., 2010) administration in humans and intraperitoneal administration in rats (Rowley et al., 2012).”
BackgroundMethodResultInfluential
Cited by
Maller, J. J., Broadhouse, K., Rush, A. J., Gordon, E., Koslow, S., & Grieve, S. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.224 · Cited by 87
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Metadata
- Authors
- Banks, M. L., Hutsell, B. A., Blough, B. E., Poklis, J. L., & Negus, S. S.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-06
- Volume
- 18
- Issue
- 8
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2011448740
- Cited by
- 42
- References
- 12
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.